Zogenix Begins Promotion of Migranal(R) Nasal Spray

Zogenix Begins Promotion of Migranal(R) Nasal Spray

Expands Portfolio of Differentiated Migraine Therapies

SAN DIEGO, Aug. 1, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a
pharmaceutical company commercializing and developing products for the
treatment of central nervous system disorders and pain, announced today that
its sales force has initiated promotion of Migranal^® (dihydroergotamine
mesylate, USP) Nasal Spray in the United States under the company's exclusive
co-promotion agreement with Valeant Pharmaceuticals North America LLC.

Roger L. Hawley, chief executive officer of Zogenix, stated, "Since entering
into our co-promotion agreement with Valeant at the end of June, we have
worked closely with their team to rapidly train our sales force to promote
Migranal, a number of whom previously promoted the product before joining
Zogenix. We are pleased to now be providing Migranal alongside SUMAVEL
DosePro, as part of a toolbox of treatment options for migraine sufferers.
This also allows us to very efficiently leverage our sales force and expertise
in migraine with our key customers. As we continue to position our commercial
operations to reach profitability, we will evaluate additional opportunities
to add innovative, complementary migraine therapies to our product portfolio
to further leverage our experienced sales force and customer focus."

The U.S. Headache Consortium's migraine treatment guidelines encourage the use
of a toolbox of treatment options to address the variety in migraine attacks.
Having Sumavel DosePro and Migranal on hand to treat specific attacks is
consistent with that approach, although the two products should not be used
within 24 hours of each other. Migranal Nasal Spray is indicated for the acute
treatment of migraine headaches with or without aura. Zogenix's commercialized
migraine product, SUMAVEL® DosePro® Needle-free Delivery System (sumatriptan
injection), is indicated for the acute treatment of migraine attacks, with or
without aura, and cluster headache.

ABOUT MIGRANAL

IMPORTANT SAFETY INFORMATION

Serious and/or life-threatening peripheral ischemia has been associated with
the coadministration of dihydroergotamine with potent CYP3A4 inhibitors
including protease inhibitors and macrolide antibiotics. Because CYP3A4
inhibition elevates the serum levels of dihydroergotamine, the risk for
vasospasm leading to cerebral ischemia and/or ischemia of the extremities is
increased. Hence, concomitant use of these medications is contraindicated.

  oMigranal Nasal Spray should not be given to patients with ischemic heart
    disease (angina pectoris, history of myocardial infarction, or documented
    silent ischemia), to patients who have clinical symptoms or findings
    consistent with coronary artery vasospasm, including Prinzmetal's variant
    angina.
  oMigranal also should not be given to patients with uncontrolled
    hypertension, patients who have used 5-HT1 agonists (e.g., sumatriptan),
    ergotamine-containing or ergot-type medications or methysergide within the
    last 24 hours, or patients with hemiplegic or basilar migraine.
  oMigranal Nasal Spray is also contraindicated in patients with known
    peripheral arterial disease, sepsis, following vascular surgery, and
    severely impaired hepatic or renal function.
  oMigranal Nasal Spray should not be administered to pregnant women or
    nursing mothers.

Migranal^®Nasal Spray should only be used where a clear diagnosis of migraine
headache has been established.

Serious cardiac events, including some that have been fatal, have occurred
following use of DHE (dihydroergotamine) 45 but are extremely rare. During
clinical studies and the foreign postmarketing experience with Migranal Nasal
Spray, there have been no fatalities due to cardiac events.

The most commonly reported adverse events in clinical trials for Migranal
Nasal Spray were rhinitis, altered sense of taste, application site reactions,
dizziness, nausea and vomiting. Adverse events associated with discontinuation
were rhinitis, dizziness, facial edema, cold sweats, accidental trauma,
depression, elective surgery, somnolence, allergy, vomiting, hypotension, and
paresthesia.

For more information on Migranal, visit http://migranal.com/migranal-home.

About SUMAVEL DosePro

SUMAVEL DosePro (sumatriptan injection) is indicated for the acute treatment
of migraine attacks, with or without aura, and the acute treatment of cluster
headache episodes.

SUMAVEL DosePro should only be used where a clear diagnosis of migraine or
cluster headache has been established. SUMAVEL DosePro is not intended for the
prophylactic therapy of migraine or for use in the management of hemiplegic or
basilar migraine and should not be administered intravenously. For a given
attack, if a patient does not respond to the first dose of SUMAVEL DosePro,
the diagnosis of migraine or cluster headache should be reconsidered before
administration of a second dose.

Important Safety Information

SUMAVEL DosePro is contraindicated in patients with uncontrolled hypertension,
in patients with history, symptoms or signs of ischemic heart disease,
coronary artery vasospasm, cerebrovascular or peripheral vascular disease
including ischemic bowel disease and in patients with other significant
underlying cardiovascular diseases or known hypersensitivity to sumatriptan.
SUMAVEL DosePro should not be given to patients in whom unrecognized coronary
artery disease is predicted by the presence of risk factors without a prior
cardiovascular evaluation.

Serious cardiovascular events, including death, have been reported when taking
sumatriptan, including patients with no findings of cardiovascular disease.
Considering the extent of use of sumatriptan in patients with migraine, the
incidence of these events is extremely low. Cerebrovascular events, some
fatal, have been reported in patients treated with sumatriptan. In a number of
cases, it appears possible that the cerebrovascular events were primary,
sumatriptan having been administered in the incorrect belief the symptoms
experienced were a consequence of migraine when they were not. It is important
to advise patients not to administer SUMAVEL DosePro if a headache being
experienced is atypical.

Do not use Sumavel DosePro and any ergotamine-containing or ergot-type
medication within 24 hours of each other; do not use SUMAVEL DosePro and
another 5-HT[1] agonist (e.g. triptan) within 24 hours of each other (with the
exception of a single dose of another sumatriptan product, provided the doses
are separated by at least 1 hour).SUMAVEL DosePro is not generally
recommended for use with MAO-A inhibitors. The development of a potentially
life-threatening serotonin syndrome may occur with triptans, including
treatment with SUMAVEL DosePro, particularly during combined use with
selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine
reuptake inhibitors (SNRIs). SUMAVEL DosePro should be used during pregnancy
only if the potential benefit justifies the potential risk.

In controlled clinical trials with sumatriptan injection, the most common
adverse reactions were injection site reactions, tingling, warm/hot sensation,
burning sensation, feeling of heaviness, pressure sensation, feeling of
tightness, numbness, feeling strange, tight feeling in head, flushing,
tightness in chest, discomfort in nasal cavity/sinuses, jaw discomfort,
dizziness/vertigo, drowsiness/sedation and headache.

For full prescribing information, please click here:
http://www.zogenix.com/downloads/SV0468.0611_SDP_PI.pdf

For more information about SUMAVEL DosePro, please visit
www.SUMAVELDosePro.com.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville,
California, is a pharmaceutical company commercializing and developing
products for the treatment of central nervous system disorders and pain.
Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection)
Needle-free Delivery System, was launched in January 2010 for the acute
treatment of migraine and cluster headache. Zogenix's lead investigational
product candidate, Zohydro™ ER (hydrocodone bitartrate extended release
capsules), is an oral, extended-release formulation of various strengths of
hydrocodone, without acetaminophen, intended for administration every 12 hours
for around the clock management of moderate to severe chronic pain. In May
2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER.
Zogenix's second investigational product candidate, Relday™, is a proprietary,
long-acting injectable formulation of risperidone for the treatment of
schizophrenia; an investigational new drug application was submitted to the
FDA in May 2012.

Forward-Looking Statements

Zogenix cautions you that statements included in this press release that are
not a description of historical facts are forward-looking statements. Words
such as "believes," "anticipates," "plans," "expects," "indicates," "will,"
"intends," "potential," "suggests," "assuming" and similar expressions are
intended to identify forward-looking statements. These statements are based on
the company's current beliefs and expectations. These forward-looking
statements include statements regarding Migranal Nasal Spray's and SUMAVEL
DosePro's usefulness as a therapeutic option in relieving migraine pain and
symptoms, the potential for the co-promotion arrangement to help Zogenix
achieve profitability and the possibility of adding complementary migraine
therapies to Zogenix's product portfolio. The inclusion of forward-looking
statements should not be regarded as a representation by Zogenix that any of
its plans will be achieved. Actual results may differ from those set forth in
this release due to the risk and uncertainties inherent in Zogenix's business,
including, without limitation: Zogenix's ability to successfully sell Migranal
Nasal Spray to Zogenix's base of prescribers; unexpected adverse side effects
relating to Migranal Nasal Spray that could result in recalls or product
liability claims; the potential early termination of the co-promote
arrangement; and other risks described in the company's prior press releases
and filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and Zogenix undertakes no
obligation to revise or update this release to reflect events or circumstances
after the date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement. This caution is made under the safe
harbor provisions of Section 21E of the Private Securities Litigation Reform
Act of 1995.

SUMAVEL^®, DosePro^®, Relday^TM and Zohydro^TM ER are trademarks of Zogenix,
Inc.

MIGRANAL® is a registered trademark of Valeant Pharmaceuticals International,
Inc. or its affiliates.

                                     FPR

CONTACT: Zogenix Contacts:
        
         Investors
         Zack Kubow
         The Ruth Group
         646.536.7020
         zkubow@theruthgroup.com
        
         Media
         Amy Wheeler
         The Ruth Group
         646.536.7025
         awheeler@theruthgroup.com
 
Press spacebar to pause and continue. Press esc to stop.